首页> 美国卫生研究院文献>Springer Open Choice >Use of platelet glycoprotein IIb/IIIa inhibitors in diabetics undergoing PCI for non-ST-segment elevation acute coronary syndromes: impact of clinical status and procedural characteristics

【2h】

Use of platelet glycoprotein IIb/IIIa inhibitors in diabetics undergoing PCI for non-ST-segment elevation acute coronary syndromes: impact of clinical status and procedural characteristics

机译：血小板糖蛋白IIb / IIIa抑制剂在接受PCI治疗的非ST段抬高的急性冠脉综合征的糖尿病患者中的使用：对临床状况和程序特征的影响

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

摘要
著录项
相似文献
相关主题

摘要

BackgroundThe most recent ESC guidelines for percutaneous coronary intervention (PCI) recommend the use of glycoprotein IIb/IIIa inhibitors (GPI) in high risk patients with non-ST-segment elevation acute coronary syndromes (NSTE-ACS), particularly in diabetics. Little is known about the adherence to these guidelines within Europe.

机译：背景技术最新的ESC经皮冠状动脉介入治疗（PCI）指南建议在非ST段抬高急性冠脉综合征（NSTE-ACS）的高危患者中使用糖蛋白IIb / IIIa抑制剂（GPI），尤其是在糖尿病患者中。关于在欧洲遵守这些准则知之甚少。

著录项

期刊名称 Springer Open Choice
作者
Timm Bauer; Helge Möllmann; Franz Weidinger; Uwe Zeymer; Ricardo Seabra-Gomes; Franz Eberli; Patrick Serruys; Alec Vahanian; Sigmund Silber; William Wijns; Matthias Hochadel; Holger M. Nef; Christian W. Hamm; Jean Marco; Anselm K. Gitt;
展开▼
作者单位

展开▼
年(卷),期 -1(99),6
年度 -1
页码 375–383
总页数 9
原文格式 PDF
正文语种
中图分类外科学;
关键词
Non-ST-segment elevation acute coronary syndrome Platelet glycoprotein IIb/IIIa inhibitor Percutaneous coronary intervention Diabetes mellitus Clinical practice;

机译：非ST段抬高的急性冠状动脉综合征;血小板糖蛋白IIb / IIIa抑制剂;经皮冠状动脉介入治疗;糖尿病;临床实践;

相似文献

外文文献
中文文献
专利

1. Use of platelet glycoprotein IIb/IIIa inhibitors in diabetics undergoing PCI for non-ST-segment elevation acute coronary syndromes: impact of clinical status and procedural characteristics [J] . Timm Bauer, Helge M?llmann, Franz Weidinger, Clinical Research in Cardiology . 2010,第6期

机译：血小板糖蛋白IIb / IIIa抑制剂在接受PCI治疗的非ST段抬高的急性冠脉综合征的糖尿病患者中的使用：对临床状况和程序特征的影响
2. Association between angiographic complications and clinical outcomes among patients with acute coronary syndrome undergoing percutaneous coronary intervention: An early ACS (Early glycoprotein IIb/IIIa inhibition in non-ST-segment elevation acute coronary syndrome) angiographic substudy [J] . PrideY.B., MohanaveluS., ZorkunC., JACC. Cardiovascular interventions . 2012,第9期

机译：经皮冠状动脉介入治疗的急性冠状动脉综合征患者的血管造影并发症与临床结局之间的关联：早期ACS（非ST段抬高急性冠脉综合征中的早期糖蛋白IIb / IIIa抑制）血管造影研究
3. Platelet inhibitors in non-ST-segment elevation acute coronary syndromes and percutaneous coronary intervention: glycoprotein IIb/IIIa inhibitors, clopidogrel or both? [J] . Matthew A Silva, Jennifer L Donovan, Pritesh J Gandhi, Vascular Health and Risk Management . 2006,第2期

机译：非ST段抬高的急性冠状动脉综合征和经皮冠状动脉介入治疗中的血小板抑制剂：糖蛋白IIb / IIIa抑制剂，氯吡格雷或两者兼而有之？
4. The Long-Term Clinical Outcomes of Platelet Glycoprotein Ilb/IIIa Inhibitor Combined with Low Molecular Weight Heparin in Patients with Acute Coronary Syndrome [C] . J.H. Kim, M.H. Jeong, Y.J. Hong, International Congress on Thrombosis . 2004

机译：血小板糖蛋白ILB / IIIa抑制剂的长期临床结果与急性冠状动脉综合征患者低分子量肝素联合
5. Platelet Inhibitors in Non-ST-Segment Elevation Acute Coronary Syndromes and Percutaneous Coronary Intervention: Glycoprotein IIb/IIIa Inhibitors Clopidogrel or Both? [O] . Matthew A Silva, Jennifer L Donovan, Pritesh J Gandhi, 2006

机译：非ST段抬高急性冠脉综合征和经皮冠状动脉介入治疗中的血小板抑制剂：糖蛋白IIb / IIIa抑制剂氯吡格雷或两者兼有？
6. Use of platelet glycoprotein IIb/IIIa inhibitors in diabetics undergoing PCI for non-ST-segment elevation acute coronary syndromes: impact of clinical status and procedural characteristics [O] . Timm Bauer, Helge Möllmann, Franz Weidinger, 2010

机译：血小板糖蛋白IIb / IIIa抑制剂在接受PCI治疗的非ST段抬高的急性冠脉综合征的糖尿病患者中的使用：对临床状况和程序特征的影响

Use of platelet glycoprotein IIb/IIIa inhibitors in diabetics undergoing PCI for non-ST-segment elevation acute coronary syndromes: impact of clinical status and procedural characteristics

摘要

著录项

相似文献

相关主题

期刊订阅